×
Corcept Therapeutics Price to Free Cash Flow Ratio 2010-2024 | CORT
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
PE Ratio
P/S Ratio
Price/Book Ratio
Price-FCF Ratio
Net Worth
Corcept Therapeutics price to free cash flow ratio from 2010 to 2024. Price to free cash flow ratio can be defined as
View More
Corcept Therapeutics Price to Free Cash Flow Ratio 2010-2024 | CORT
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
PE Ratio
P/S Ratio
Price/Book Ratio
Price-FCF Ratio
Net Worth
Corcept Therapeutics price to free cash flow ratio from 2010 to 2024. Price to free cash flow ratio can be defined as
Related Stocks
Company Name
Market
Cap
Zoetis (ZTS)
$88.7B
Takeda Pharmaceutical (TAK)
$47.3B
Merck (MKGAF)
$23.7B
Astellas Pharma (ALPMY)
$21.5B
Summit Therapeutics (SMMT)
$19B
Sandoz Group AG (SDZNY)
$17.5B
United Therapeutics (UTHR)
$15.4B
Shionogi (SGIOY)
$13.3B
Neurocrine Biosciences (NBIX)
$12.4B
Catalent (CTLT)
$11B
Orion OYJ (ORINY)
$7.4B
Revolution Medicines (RVMD)
$7.3B
Jazz Pharmaceuticals (JAZZ)
$6.9B
Ionis Pharmaceuticals (IONS)
$6.1B
Hikma Pharmaceuticals Plc (HKMPF)
$5.7B
Madrigal Pharmaceuticals (MDGL)
$5.1B
Crinetics Pharmaceuticals (CRNX)
$4.2B
Dyne Therapeutics (DYN)
$3.5B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.7B
PTC Therapeutics (PTCT)
$2.7B
Arrowhead Pharmaceuticals (ARWR)
$2.5B
Catalyst Pharmaceuticals (CPRX)
$2.4B
Soleno Therapeutics (SLNO)
$2.1B
Recursion Pharmaceuticals (RXRX)
$1.9B
Centessa Pharmaceuticals (CNTA)
$1.8B
Xencor (XNCR)
$1.6B
BioCryst Pharmaceuticals (BCRX)
$1.6B
Harrow (HROW)
$1.5B
Cassava Sciences (SAVA)
$1.5B
Ardelyx (ARDX)
$1.4B